NCT01203124View on ClinicalTrials.gov

A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

February 29, 2012

Conditions

Healthy Volunteers

Interventions

DRUG

AZD8848

The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.

DRUG

Placebo

Trial Locations (1)

Unknown

Research Site, Uppsala